Teva Pharmaceutical Industries Limited
TEVA
NYSE·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $42.3B
$36.36
▼ -0.71%
P/E
-213.88
Mkt Cap
$42.3B
52-Wk Range
$18.21–$38.37
52-Week Range
$18.21 - $38.37
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 88.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
Turning profitable
Value
Fairly valued vs sector peers
Momentum
Strong
+9.3% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying TEVA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
JUL 29, 2026
Reported EPS of $0.02 vs $0.08 consensus (-75.0% surprise). Revenue of $4.1B vs $4.0B expected (+3.0%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-75.0%
Revenue trend · last 2Q
—
-1%
Q1 26
Q2 26
$4.0B
$4.1B
Margins · last 2Q
Gross
52.0%
Operating
3.6%
Profit
-13.9%
Wall Street consensus
6 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: UBS · Sep 4, 2026
vs Industry
How TEVA stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.